|
Price: $1.8800
$-0.05 
-2.591%
|
| Day's High:
| $1.96
| Week Perf:
| -13.36 %
|
| Day's Low: |
$ 1.84 |
30 Day Perf: |
-27.41 % |
| Volume (M): |
422 |
52 Wk High: |
$ 9.25 |
| Volume (M$): |
$ 794 |
52 Wk Avg: |
$3.91 |
| Open: |
$1.94 |
52 Wk Low: |
$1.84 |
|
|
| Market Capitalization (Millions $) |
282 |
| Shares
Outstanding (Millions) |
150 |
| Employees |
100 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-226 |
| Cash Flow (TTM) (Millions $) |
-159 |
| Capital Exp. (TTM) (Millions $) |
4 |
Erasca Inc
Erasca Inc is a biotech company dedicated to discovering and developing innovative therapies for the treatment of cancer. The company was founded in 2018 and is headquartered in San Diego, California. Its mission is to eradicate cancer by developing precision medicines that target the root causes of the disease.
The core technology of Erasca is focused on precision medicine, which involves developing targeted therapies based on genetic and molecular information of individual patients. This technology allows the company to develop drugs that specifically target cancer cells, while minimizing harm to healthy cells in the body. Erasca has a number of proprietary drug discovery platforms that enable the development of these targeted therapies.
One of Erasca's flagship products is Erava, a targeted therapy designed to treat patients with solid tumors. This drug is currently in phase 1/2 clinical trials and has shown promising results in early testing. Erasca is also developing other products, including ERAS-007, a potential treatment for patients with KRAS-mutated cancer, and a range of antibody-drug conjugates (ADCs) that target different types of cancer cells.
The company's leadership team is composed of industry veterans with extensive experience in the development of oncology drugs. They bring a diverse range of expertise across drug discovery, clinical development, and regulatory affairs. Erasca has also formed strategic collaborations with leading institutions in the field of cancer research, such as MD Anderson Cancer Center and Children's Hospital Los Angeles.
Erasca has received significant support from institutional investors, raising more than $300 million in funding since its inception. The company is also committed to social responsibility, partnering with organizations like Stand Up To Cancer to help fund cancer research and raise awareness about the disease. Overall, Erasca represents a promising new entrant in the field of oncology drug development, with a strong focus on precision medicine and a commitment to making a meaningful impact in the fight against cancer.
Company Address: 3115 Merryfield Row San Diego 92121 CA
Company Phone Number: 465-6511 Stock Exchange / Ticker: NASDAQ ERAS
| ERAS is expected to report next financial results on November 08, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Renovaro Biosciences Inc
Renovaro Biosciences Inc, a major pharmaceutical preparations company, has released its financial report for the fiscal period ending June 30, 2023. During this period, the company experienced zero gain per share, an improvement compared to the same period a year ago when it reported a gain of $0.33 per share. It also represents an increase from the preceding financial reporting period when the company reported a loss of $0.08 per share.
In terms of revenue, Renovaro Biosciences Inc did not experience any change compared to the corresponding financial reporting period a year ago. The revenue remained at $0.00 million, and there was no sequential change either. This stability in revenue could be an area of concern for the company, as it suggests a lack of growth or expansion in its operations.
|
|
Immuron Limited
In the financial fourth quarter of 2023, Immuron Limited, a major pharmaceutical preparations company, reported its financial results, which revealed a decrease in revenue and widened net loss. These figures mark a notable change compared to the corresponding financial reporting period from the previous year. This article aims to examine the context behind Immuron Limited's financial results, including its stock performance and implications for investors.
Financial Results:
Immuron Limited disclosed a revenue of $1.480365 million in the financial fourth quarter of 2023 after experiencing a net loss of $-3.787 million. These figures signify a departure from balanced books in the corresponding period a year earlier. Additionally, in the financial year 2023, the company announced a loss of $-3.79 million alongside a revenue of $1.48 million. In comparison to the prior financial year, the net loss per share has widened from $-1.25 to $-1.66, indicating a financial decline. However, it is important to note that the net loss remained unchanged from $0.00 million a year earlier.
|
|
Procyon Corporation
Procyon Corporation recently released their financial results for the fourth quarter of the 2023 earnings season. While the company reported unaltered earnings per share (EPS), a decline in revenue and other key indicators raises concerns about the company's future performance. This article aims to interpret the financial results and discuss their potential impact on Procyon Corporation going forward.
1. Earnings per Share (EPS) and Revenue Performance:
Procyon Corporation maintained an EPS of $0.00 in the fourth quarter, suggesting stability in their profitability. However, the company experienced a modest revenue decline of -0.589% year-on-year, amounting to $1.20 million. This decline sets Procyon apart from the rest of the Major Pharmaceutical Preparations industry, which recorded a revenue improvement during the same period.
|
|
Innovation Pharmaceuticals Inc
Innovation Pharmaceuticals Inc, a pharmaceutical company, recently announced its financial results for the fiscal year ending June 30, 2023. During this period, the company achieved a break-even point of $0.00 per share, which was the same as the previous year and the previous quarter.
However, the company did not generate any revenue during this quarter, remaining at $0.00 million, the same as the previous year and quarter. This indicates that there was no growth in the company's revenue during this period.
Additionally, Innovation Pharmaceuticals Inc reported a net shortfall of $-0.681 million for the fiscal year ending June 30, 2023. This is a significant improvement compared to the deficit of $-1.626 million reported in the same quarter a year ago. Although still in a shortfall, the company has managed to reduce its losses, which may indicate positive efforts in managing their expenses.
|
|
Palatin Technologies Inc
Financial News Report:
Palatin Technologies Inc Reports Strong Revenue Growth in Q4 2023, Despite Stock Deficit
Palatin Technologies Inc (PTN) has announced a substantial revenue advancement of 109.038% year on year to $1.76 million in the fourth quarter of 2023. However, the company posted a deficit per stock at $-0.98. Despite the stock deficit, PTN's revenue experienced significant growth compared to its peers in the Major Pharmaceutical Preparations industry. Most corporations in this industry saw an average revenue advance of 3.04% during the same period.
In comparison to the preceding reporting period, PTN's revenue surged by 47.359% from $1.20 million and the deficit improved from $0.00 per share. This strong revenue growth indicates a positive trend for Palatin Technologies Inc.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.23 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
2.11 $
|
| Book Value |
2.42 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.23 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
2.11 $
|
| Book Value |
2.42 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
